Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 21,412 matching trials from the live ClinicalTrials.gov search.
Conditions
Stage IIIB Merkel Cell Carcinoma, Stage IV Merkel Cell Carcinoma
Interventions
aNK (NK-92), aNK (NK-92) + N-803
Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Chicago, Illinois • Pittsburgh, Pennsylvania • Seattle, Washington
Conditions
Small Cell Lung Cancer
Interventions
Dinutuximab, Irinotecan, Topotecan
Biological · Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
40
States / cities
Anchorage, Alaska • Goodyear, Arizona • Tucson, Arizona + 35 more
Conditions
Recurrent Ovarian Cancer, Recurrent Fallopian Tube Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Relacorilant, Nab-paclitaxel
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
12
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Denver, Colorado + 6 more
Conditions
Glioma
Interventions
bevacizumab, carmustine
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Sacramento, California
Conditions
Polycythemia Vera
Interventions
Gleevec
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
New York, New York
Conditions
Non-small-cell Lung Cancer
Interventions
XL647
Drug
Lead sponsor
Kadmon Corporation, LLC
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
7
States / cities
Port Saint Lucie, Florida • Chicago, Illinois • Urbana, Illinois + 4 more
Conditions
Asthma
Interventions
tiotropium bromide, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years to 17 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
5
States / cities
Denver, Colorado • Columbia, Missouri • Warrensburg, Missouri + 2 more
Conditions
Endometrial Cancer
Interventions
medroxyprogesterone
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
30
States / cities
Tucson, Arizona • Los Gatos, California • Orange, California + 26 more
Conditions
HIV Infections
Interventions
ALVAC(2)120(B,MN)GNP (vCP1452), MN rgp120/HIV-1 and GNE8 rgp120/HIV-1
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2003
U.S. locations
17
States / cities
Birmingham, Alabama • San Francisco, California • Baltimore, Maryland + 9 more
Conditions
Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage IIIB Gastric Cancer, Stage IIIC Gastric Cancer, Stage IV Gastric Cancer
Interventions
bortezomib, irinotecan
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
Interventions
bromodeoxyuridine, conventional surgery, laboratory biomarker analysis
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Male only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Clemastine, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
San Francisco, California
Conditions
Metastatic Cancer
Interventions
mitomycin C
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Thyroid Neoplasms
Interventions
Lenalidomide
Drug
Lead sponsor
Kenneth Ain
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Non-small Cell Carcinoma, Adenocarcinoma of Lung, Squamous Cell Carcinoma, Large Cell Carcinoma, Lung Neoplasms
Interventions
Drug: Hyperacute Lung Cancer Cell Vaccine
Biological
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
21 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Metastatic Breast Cancer
Interventions
Palliative Radiation and Pembrolizumab
Combination Product
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma, Raynaud's Disease Secondary to Autoimmune Disease
Interventions
MQX-503
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Timeline
2006
U.S. locations
1
States / cities
Renton, Washington
Terminated Phase 2 Interventional Results available

Phase 2 RCT of Alvimopan vs. Placebo After CRS/HIPEC

NCT03352414
Conditions
Ileus
Interventions
Alvimopan, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
La Jolla, California
Completed Phase 1Phase 2 Interventional Results available

PD 0332991 and Cetuximab in Patients With Incurable SCCHN

NCT02101034
Conditions
Carcinoma, Squamous Cell of Head and Neck
Interventions
Cetuximab, PD 0332991
Biological · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
5
States / cities
Atlanta, Georgia • Westwood, Kansas • Ann Arbor, Michigan + 2 more
Conditions
Colorectal Cancer
Interventions
edrecolomab, sargramostim
Biological
Lead sponsor
James Ahlgren
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
HIV Infections, AIDS
Interventions
L-carnitine, Placebo
Drug · Other
Lead sponsor
National Institute of Nursing Research (NINR)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
New York, New York
Conditions
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Osteopenia, Osteoporosis
Interventions
Denosumab
Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Buffalo, New York • Cleveland, Ohio
Conditions
Metastatic Osteosarcoma
Interventions
doxorubicin hydrochloride, cisplatin, methotrexate, leucovorin calcium, filgrastim, therapeutic conventional surgery, radiation therapy, etoposide, ifosfamide, trastuzumab, laboratory biomarker analysis
Drug · Biological · Procedure + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 30 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Arcadia, California
Conditions
Chronic Myelogenous Leukemia
Interventions
Gleevec (imatinib), valproic acid
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Albuquerque, New Mexico